Jun. 3 at 5:51 PM
$BCYC Nectin-4 BTC (Bicycle Toxin Conjugate) which is basically an ADC, had decent results in 1st line cisplatin ineligible patients. As of 3 Jan 2025, 22 pts were enrolled from Nov 2023 to Jul 2024 with a median time on treatment of 22.9 weeks and 12 pts still receiving study treatment. Median age was 77 years; 46% of pts had an ECOG performance status (PS) of 2; 55% with CrCl < 60 mL/min. With 20 efficacy evaluable pts, the ORR is 65.0% (95% CI, 40.8, 84.6), including 5 CRs (25.0%; 4 confirmed), 8 PRs (40.0%; 6 confirmed) and 5 SD (25.0%). Median follow-up was 7.1 mo (range 1.0 – 13.2) and median duration of response was not reached. DCR is 90.0%. The most common grade (Gr) ≥3 TRAEs included ALT increased and neutropenia (13.6% each), and diarrhea, asthenia, hypomagnesemia, and pneumonia (9.1% each). Serious TRAEs related to zele or zele + pembro occurred in 9.1%. Treatment-related peripheral neuropathy occurred in 50.0% (27.3% Gr1, 13.6% Gr2, 9.1% Gr3).